Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + BCG in High-Risk NMIBC
NCT07207824Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2025
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of disitamab vedotin in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Fudan University. Primary endpoint: Event-Free Survival at 55 months. Started Dec 2025; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07207824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207824.